<p>The interleukin-6 (IL-6) antibody pacibekitug produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the Phase II TRANQUILITY trial presented in a Hot Line session at ESC Congress 2026.</p>